Investor Center

Investor Center

Corporate Profile

Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

Recent Press Releases

November 12, 2021
CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical research demonstrating the ability of the company’s multiplex edited CAR T cells to target